# Biomarker and DNA Collection in Subjects Participating in Protocol 22003

> **NCT00892580** · — · COMPLETED · sponsor: **Seaside Therapeutics, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Fragile X Syndrome

## Interventions

- **DRUG:** STX209

## Key facts

- **NCT ID:** NCT00892580
- **Lead sponsor:** Seaside Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2010-06
- **Final completion:** —
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2013-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00892580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00892580, "Biomarker and DNA Collection in Subjects Participating in Protocol 22003". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00892580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*